Why the study?
Treatment strategies for HFpEF remain elusive, with unclear guidance and inconclusive clinical evidence regarding the use and effects of beta-blockers.
Do beta-blockers improve clinical outcomes in patients with HFpEF?
Do beta-blockers improve clinical outcomes in patients with HFpEF?
The role of beta-blockers in HFpEF remains inconclusive, with potential benefits on mortality but risks of exacerbating chronotropic incompetence, necessitating further large-scale RCTs.
Answers are grounded in this paper and cite their sources.
No change to HFpEF management indicated; leaves open potential mortality benefit pending large RCTs.
Heart failure with preserved ejection fraction (HFpEF) poses a significant challenge in contemporary medicine, characterized by poor quality of life, high healthcare costs, and increased mortality. Despite advancements in medical research, treatment strategies for HFpEF remain elusive, with unclear guidance on the use of beta-blockers. While sympathetic overstimulation is common in HFpEF, beta-blockers, though potentially beneficial in reducing sympathetic activity, may exacerbate chronotropic incompetence and decrease exercise tolerance. Additionally, their impact on outcomes in HFpEF patients with concurrent atrial fibrillation is uncertain. Some studies suggest the potential benefits of beta-blockers on diastolic function, yet evidence on clinical endpoints remains inconclusive. Recent research indicates a potential reduction in all-cause mortality with beta-blocker use in HFpEF, although their effect on combined mortality or HF hospitalizations is less clear. Moreover, beta-blocker efficacy may vary depending on ejection fraction subgroups, with more favorable outcomes observed in HFmrEF compared to HFpEF. Current literature underscores the need for large-scale randomized clinical trials to clarify the role of beta-blockers in HFpEF management. Given the limitations of existing evidence, future research is essential to inform updated treatment guidelines and therapeutic protocols tailored to the contemporary clinical landscape.
No takes yet. Share an insight, caveat, or question.
Tokarczyk et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: